// App-Quantinova.ai

P149 : Axonal Integrity by MRS at Baseline in the SPI2 Ph3 Trial of MD1003 (hdPB): Effect of Sex, Disease Burden, and Progressive MS Type

Researchers

Presenter

  • S. Narayanan

Principal Investigators

  • G. Cutter

  • J. Wolinsky

  • M. S. Freedman

  • G. Comi

  • G. Giovannoni

  • H. Hartung

  • F. Sedel

  • F. D. Lublin

  • S. Antel

  • D. L. Arnold

  • B. A. Cree

Medical Centers

  • Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada

  • UAB Sch of Public Health, Birmingham, AL

  • The University of Texas Health Science Center at Houston, Houston, TX

  • University of Ottawa, and Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Department of Neurology and Institute of Experimental Neurology, San Raffaele Hospital, Milan, Italy

  • Barts and the London School of Medicine, London, United Kingdom

  • Department of Urology, Heinrich-Heine-University, Duesseldorf, Germany

  • Medday Pharmaceuticals Paris France

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • NeuroRx Research, Montreal, QC, Canada

  • Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA San Francisco CA United States

Locations

  • Canada

  • United States

  • Italy

  • United Kingdom

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • MD1003

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved